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Abstract
Background: The aim of this paper is to analyze changes in thyroid cancer incidence trends in
Lithuania during the period 1978–2003 using joinpoint regression models, with special attention to
the period 1993–2003.
Methods: The study was based on all cases of thyroid cancer reported to the Lithuanian Cancer
Registry between 1978 and 2003. Age group-specific rates and standardized rates were calculated
for each gender, using the direct method (world standard population). The joinpoint regression
model was used to provide estimated annual percentage change and to detect points in time where
significant changes in the trends occur.
Results: During the study period the age-standardized incidence rates increased in males from 0.7
to 2.5 cases per 100 000 and in females from 1.5 to 11.4 per 100 000. Annual percentage changes
during this period in the age-standardized rates were 4.6% and 7.1% for males and females,
respectively. Joinpoint analysis showed two time periods with joinpoint in the year 2000. A change
in the trend occurred in which a significant increase changed to a dramatic increase in thyroid
cancer incidence rates. Papillary carcinoma and stage I thyroid cancer increases over this period
were mainly responsible for the pattern of changes in trend in recent years.
Conclusion: A moderate increase in thyroid cancer incidence has been observed in Lithuania
between the years 1978 and 2000. An accelerated increase in thyroid cancer incidence rates took
place in the period 2000–2003. It seems that the increase in thyroid cancer incidence can be
attributed mainly to the changes in the management of non palpable thyroid nodules with growing
applications of ultrasound-guided fine needle aspiration biopsy in clinical practice.
Background
Thyroid cancers constitute 1% of all malignancies world-
wide and are heterogenous in terms of histology, clinical
presentation, treatment response and prognosis. The
annual incidence of thyroid cancer varies considerably in
different registries. High incidence rates in Hawaii, Ice-
land and Israel have been known for some years. For the
most recent data, female Hawaiians, Icelanders, Israeli
Jews and Austrian Tyrolese have rates in the range of 8.5 –
19.4 per 100 000 [1]. In Europe, the highest incidence
occurs in Iceland, followed by Austria and Finland, while
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relatively low incidence characterizes the UK, Netherlands
and Denmark.
The only established risk factor for thyroid cancer in
humans, besides age and gender, is ionizing radiation [2].
Sex hormones, iodine deficiency and other factors have
been proposed as risk factors for thyroid cancer, but the
findings are inconsistent [3-7].
The incidence of thyroid cancer is increasing in some
European countries, USA and Canada [8-11]. The increase
in thyroid cancer incidence in Lithuania, observed over
the last 20 years, has raised public concern about its asso-
ciation with the Chernobyl nuclear power plant accident
in 1986 [12]. Post-Chernobyl studies of thyroid cancer
incidence in Belorussia and Ukraine have showed an
increased risk, especially those covering population of the
most contaminated areas [13]. Thyroid cancer trends in
other countries neighboring Belorussia and Ukraine can
help validate the risk assessment and explain the rather
high country rate variation.
The aim of this study is to analyze changes in thyroid can-
cer incidence trends in Lithuania during the period 1978–
2003 using joinpoint regression models [14].
Methods
Data on thyroid cancer incidence for the years 1978
through 2003 were obtained from the Cancer Registry of
Lithuania (Registry). The Registry covers the entire popu-
lation of the Republic of Lithuania (3.48 million at the
2001 census) and is located at the national cancer center
recently operating as Vilnius University Institute of Oncol-
ogy, where more that 50% of cancer patients in Lithuania
are admitted for treatment. The main sources of data are
notifications gathered from all hospitals and diagnostic
centers in Lithuania. This information is completed by
death certificates stating cancer diagnosis, and by notifica-
tions from regional health centers. In 2003, 1.5% of all
new cancer cases were registered from death certificates
only and 85.7% of diagnoses were confirmed microscop-
ically.
The study was based on all cases of thyroid cancer
reported to the Registry during 1978–2003. Correspond-
ing population data, by age, sex and year were available
from Department of Statistic of the Republic of Lithuania.
Analyses were based on new cases of invasive thyroid can-
cer (International Classification of Disease – Oncology, 1st
edition, site codes 1930–1939 for the period 1978–1997,
and International Classification of Disease – Oncology, 2nd
edition, site codes C730-C739 for the period 1998–
2003).
A more detailed analysis by histopathology and stage of
disease was performed for the period 1993–2003. Analy-
sis was limited to this period because detailed and reliable
information on histology and stage is not available for
patients diagnosed before 1993. During the period 1993–
2003 the TNM system was used for coding the stage of dis-
ease and International Classification of Diseases – Oncology,
for coding of morphology (1st edition, for the period
1993–1997 and 2nd edition for later period).
Age-specific and age-standardized incidence rates were
calculated. Standardization was performed using the
direct method (world standard population). Age-stand-
ardized rates were calculated for each calendar year, for all
ages combined and age-specific rates for age groups 0–19,
20–44, 45–64 and 65 and over.
The joinpoint regression analysis was used to identify
points where a statistically significant change over time in
linear slope of the trend occurred [14]. The analysis starts
with the minimum number of joinpoints, and tests
whether one or more joinpoints are statistically significant
and should be added to the model. The tests of signifi-
cance use a Monte Carlo permutation method. In the final
model, each joinpoint indicates a statistically significant
change in trend, and an estimated annual percentage
change (EAPC) is computed for each of those trends by
means of generalized linear models assuming a Poisson
distribution. A maximum number of 3 joinpoints was
allowed for estimations. Joinpoint analysis was per-
formed for all ages combined and age-specific rates for the
following age groups 0–19, 20–44, 45–64, and 65 and
over. A Joinpoint software version 2.6 was used [15].
Results
Changes in thyroid cancer incidence
In the year 2003 there were 47 thyroid cancer cases in
males and 280 in females in Lithuania. This represents
0.6% and 3.7%, respectively, of all new malignant
tumours. Incidence rates were considerably lower for
males than for females, with male:female ratio 1:3. Thy-
roid cancer incidence rates in males changed during the
study period from 0.7/100 000 in 1978 to 2.5/100 000 in
the year 2003, and from 1.5/100 000 to 11.4/100 000 in
females (Figure 1).
Age-specific thyroid cancer incidence rates are shown in
Figure 2. In females thyroid cancer incidence increases
steadily up to 65 years of age, and decreases thereafter. Lit-
tle change in the male's thyroid cancer age-specific inci-
dence rates was observed.
Results of the joinpoint analysis of incidence time trends
are shown in Table 1. Annual percentage changes in the
age-standardized rates over this period were 4.6% andBMC Cancer 2006, 6:284 http://www.biomedcentral.com/1471-2407/6/284
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7.1% for males and females, respectively, for all thyroid
carcinomas combined.
Joinpoint analysis does not show the existence of statisti-
cally significant points of change in male thyroid cancer
incidence. Age group analysis revealed that for the entire
study period, rates increased significantly in almost all age
groups except one. In age group 20–44 incidence started
to increase by 29.7% per year since 1999.
In females, after a moderate increase of 5.2% per year
until 2000, a sharp increase in incidence occurred, reach-
ing 29.8% per year in recent years. The year 2000 was rec-
ognized as a statistically significant change point in
incidence trend for the age group 20–44 years. In the age
group 45–64 years, moderate increase was followed by a
dramatic increase in period 1999–2003.
Thyroid cancer incidence analysis by sex and age group
revealed that for the entire study period rates increased
significantly in both sexes and in almost all age groups.
However, joinpoint analysis makes it possible to distin-
guish two time periods: an initial period of statistically
significant increase and a second period of a dramatic rate
increase. In the year 2000, a change in females thyroid
cancer incidence trend occurred in the age group 20–44
years and overall rates in which a significant increase
changed to an accelerated increase. The same pattern of
increase was observed for males in the age group 20–44
and for females in the age group 45–64 years with join-
point in year 1999.
Changes in thyroid cancer incidence by histopathology and 
by stage in 1993–2003
Results of the joinpoint analysis of trends by histopathol-
ogy and stage of disease, for both sexes combined, are
shown in Table 2. Also there were changes in thyroid can-
cer incidence rates, with increases in papillary and follicu-
lar carcinoma. Estimated annual percentage changes over
this period were 11.4% for all thyroid carcinomas com-
bined; 17.7% for papillary carcinoma and 9.2% for follic-
ular carcinoma. A statistically significant change in trend
was found in papillary and follicular thyroid carcinoma
incidence in 1999 and 2001 years respectively.
Joinpoint analysis by stage of disease showed the highest
increase in I stage thyroid cancer, with statistically signifi-
cant change in trend in the year 2000.
Discussion
In Lithuania, as in many other countries, the incidence of
thyroid cancer is increasing. Most probably, the trends
Age-standardised (per 100 000 world standard) thyroid cancer incidence rates in Lithuania, 1998–2003 Figure 1
Age-standardised (per 100 000 world standard) thyroid cancer incidence rates in Lithuania, 1998–2003.
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reflect an environmental risk increase that is boosted by
augmented diagnostic activity following more careful
pathological examination.
The increase in thyroid cancer risk could be attributed to
ionizing radiation exposure [2]. Environmental and occu-
pational exposures from the Chernobyl accident were
studied in Lithuania – the recent estimates do not confirm
an evident contribution to thyroid cancer rates for the
Lithuanian population. In a study of Lithuania clean-up
workers, no elevated thyroid cancers risk due to exposure
was detected. There was no association with the level of
radiation dose or duration of stay in the area of Chernobyl
[16]. Studies of individuals living in the Chernobyl areas
have shown an increased risk among those exposed as
children [13]. In Lithuania in 1987 thyroid cancer inci-
dence rates for males and females, in age group 0–19 years
were 0.2 and 0.6 per 100 000 and in 2003 0.9 and 0.6
respectively. Ionizing radiation exposure, therefore can-
not explain the recent increase in incidence of thyroid
cancer in Lithuania; other factors should have contributed
importantly to the changing pattern.
In addition to this well-known risk factor of thyroid can-
cer, the increase of diagnostic activity has been suspected
to be of etiological importance in the observed increase of
thyroid cancer incidence. Analysis of the impact of
changes in medical practice found an association between
the spread of fine-needle aspiration biopsy and the
increase in thyroid cancer incidence [17]. In Lithuania, the
overall thyroid cancer increase was caused primarily by an
increase in papillary thyroid cancer and in I stage thyroid
cancer. Ultrasound guided fine-needle aspiration biopsy
of thyroid nodules was first introduced in Lithuania in
1997. At about at the same time, the practice of follow-up
of small thyroid nodules was changed accordingly. The
method of ultrasound guided aspiration biopsy of asymp-
tomatic thyroid nodules smaller than 1 cm in diameter
was employed for the follow-up. If one takes into consid-
eration the dynamic of fine-needle aspiration biopsy dis-
semination in the region, then the increase in thyroid
cancer incidence would seem to be correlated well with
the new diagnostic technology.
Studies from other countries confirm our suggestions of
the possible impact of changes in the management of thy-
roid nodules and diagnostic activities. Increase in papil-
lary thyroid cancer incidence in Geneva has been found to
be related mainly to changes in histological diagnostic cri-
teria, and, to a lesser extent, to increased diagnostic activ-
Age-specific thyroid cancer incidence rates in Lithuania, 1978–2003 Figure 2
Age-specific thyroid cancer incidence rates in Lithuania, 1978–2003.
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ity [18]. The proportion of microcarcinomas and silent
carcinomas increased from 17% to 24% between 1970–
79 and 1990–98. A multicentric study in France showed a
significant increase, from 1980 to 2000, in ultrasono-
graphic (from 3 to 84.8%) and fine-needle aspiration
biopsy (from 4,5 to 23%) of patients with thyroid nodules
as well as a significant association between the increase in
the prevalence of thyroid carcinomas among operated
patients (from 12.5 to 37) [17]. There was increased inci-
dence of thyroid cancer in France, mainly due to papillary
type, with an epidemic of microcarcinomas (43% of oper-
ated cancers, for the period 1998–2001) [9].
The increasing incidence of thyroid cancer in the United
States also was related to the increased detection of small
papillary cancers. Between 1988 and 2002, 49% of the
increase consisted of cancers measuring 1 cm or smaller;
87% consisted of cancers measuring 2 cm or smaller [10].
The authors suggested that increasing incidence with sta-
ble mortality rates reflects increased detection of subclini-
Table 2: Thyroid cancer joinpoint analysis by stage and histopathology (1993–2003).
1993 2003 EAPC 1978–2003 Trend 1 Trend 2
N Rate N Rate Years EAPC Years EAPC
All cases 128 3.5 325 9.4 11.4* 1993–2000 5.3* 2000–2003 27.5*
Histopathology
papillary 58 1.6 249 7.2 17.7* 1993–1999 6.2 1999–2003 33.2*
follicular 16 0.4 47 1.4 9.2* 1993–2001 4.7 2001–2003 32.3
other 54 1.5 29 0.8 -2.4 1993–2003 -2.4
Stage
I 12 0.3 162 4.7 29.6* 1993–2000 14.6 2000–2003 58.9*
II 66 1.8 66 1.9 3.5 1993–2003 3.5
III 19 0.5 80 2.3 17.1* 1993–2003 17.1*
IV 20 0.5 16 0.5 5.0 1993–2001 10.5* 2001–2003 -33.1
unspecified 11 0.3 1 0.03 -18.6* 1993–2003 -18.6*
*The EAPC is significantly different from 0 (P < 0.05).
EAPC – estimated annual percentage change.
Table 1: Thyroid cancer incidence rates and joinpoint analysis (1978–2003).
1978 2003 EAPC 1978–2003 Trend 1 Trend 2
N Rate N Rate Years EAPC Years EAPC
Males
Age (years)
00–19 0 0.0 4 0.9 4.8* 1978–2003 4.8*
20–44 4 0.7 26 4.2 5.8* 1978–1999 2.5 1999–2003 29.7*
45–64 5 1.7 12 3.4 4.9* 1978–2003 4.9*
65+ 1 0.7 5 2.9 2.2 1978–2003 2.2
Standardized 10 0.7 47 2.5 4.6* 1978–2003 4.6*
(95% PI) (0.2–1.1) (1.8–3.2)
Females
Age (years)
00–19 0 0.0 2 0.4 1.2 1978–2003
20–44 8 1.3 82 12.9 7.3* 1978–2000 5.1* 2000–2003 31.5*
45–64 13 3.3 141 32.7 9.3* 1978–1999 6.5* 1999–2003 26.9*
65+ 15 6.3 55 16.4 3.7* 1978–2003
Standardized 36 1.5 280 11.4 7.1* 1978–2000 5.2* 2000–2003 29.8*
(95% PI) (1.0–2.0) (10.0–12.8)
*The EAPC is significantly different from 0 (P < 0.05).
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cal disease, not an increase in the true occurrence of
thyroid cancer. Most probably, increased thyroid cancer
incidence rates in Lithuania may also be attributed to
diagnostic improvements and, consequently, to the dis-
covery of smaller tumours.
The joinpoint analysis has recognized evident changes
only by years 1999 and 2000 that can be a reflection of
major changes in diagnostic and treatment paradigms and
new diagnostic technology in the country. The results
show changes in thyroid cancer incidence, and the relative
importance of the diagnostic activities in recent years.
Additional research on the risk factors for thyroid cancer
and incidence changes related to diagnostic practices is
needed to explain the peaking of the incidence rates in
Lithuania.
Conclusion
A moderate increase in thyroid cancer incidence has been
observed in Lithuania between the years 1978 and 2000.
An accelerated increase in thyroid cancer incidence rates
took place in the period 2000–2003. It seems that the
increase in thyroid cancer incidence can be attributed
mainly to the changes in the management of non palpa-
ble thyroid nodules with the growing application of ultra-
sound-guided fine needle aspiration biopsy in clinical
practice.
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